ENDING OPIOID USE

Published on Newsmax.

Those suffering from America’s opioid crisis recently received two major messages of hope.

On October 24, President Donald Trump signed the Opioid Crisis Response Act (OCRA) into law. Dozens of bills designed to address the diverse aspects of the opioid crisis were consolidated into one strategic and integrated approach. OCRA received overwhelming bi-partisan support in both Chambers.

HR6, which is now Public Law 115-271, broke new ground in being the first legislation to mandate aggressive development and adoption of alternative pain treatments that include “innovative medical technologies for pain management”.

On October 11, Congress held its first ever briefing on ending opioid use through “innovative medical technologies for pain management”.

Photobiomodulation (PBM) was the featured technology.

James Carroll (CEO, THOR Photomedicine), Professor Praveen Arany (New York University at Buffalo), Annette Quinn RN (Radiation Oncology, University of Pittsburgh (UPMC) Cancer Center) introduced the science and promise of PBM Therapy to a capacity crowd of senior policy officials from House and Senate offices, the Executive Branch, and leading think tanks. Nineteen science and medical organizations sponsored this historic gathering.

PBM Therapy delivers a beam of light, which when applied to the body at the right wavelength (red to near infra-red), intensity and time, reverses the disease process of a growing number of medical conditions. It works by delivering light to the hundreds of mitochondria that exist in every one our body’s 37 trillion cells. This provides an energy boost that helps the cells repair and operate at peak performance.

There are already 500 clinical trials and 4,000 laboratory studies that show PBM Therapy’s effectiveness, without any documented side-effects. "PBM Therapy is commonly used in Australia, Brazil, Canada, New Zealand, and most European nations. The national health programs in many of these countries cover PBM treatments.”

The United States has been slow to embrace PBM Therapy. American Veterinarians and athletes have used it for years to treat pain. The urgency of the opioid crisis, and the new mandate for pain treatment alternatives, may finally bring this proven approach to those who need it.

The study mandated by the newly signed Opioid Crisis Response Act (OCRA) will be led by the Secretary of Health and Human Services (HHS). This is important, as Medicare and Medicaid can dramatically reduce health costs when patients use PBM Therapy. Quicker recovery time, no side effects, shorter hospital stays, and reduced return visits have cut costs by nearly fifty percent in the United Kingdom. PBM use would substantially reduce costs to both patients and private health insurance companies.

The next steps for PBM Therapy adoption are mandated in the OCRA law, including research grants to fund further basic science experiments, therapeutic dose, and large multi-center clinical trials. OCRA also funds “regional centers of excellence” to develop curriculum and train the next generation of healthcare professionals in non-opioid pain treatments.

Harvard University’s Medical School is discovering that PBM reverses Alzheimer’s, Parkinson’s, treats depression and Post-traumatic stress disorder (PTSD). Boston University is working with the Veterans Administration on depression, traumatic brain injury (TBI), and PTSD. University of Pittsburgh’s Medical Center and New York University’s Medical College are proving that PBM Therapy reverses and even prevents the side effects of cancer radiotherapy, especially oral mucositis.

Shepherd University will be the first nursing school in America to formally include PBM Therapy in their curriculum. Shepherd is leading the way on revolutionizing medical protocols for the betterment of patients and their loved ones. Hopefully, other schools will join the PBM Therapy movement.

The Food and Drug Administration (FDA) has spent over a year determining how to expand its PBM Therapy approval. This includes establishing a dedicated PBM Product Code, and officially recognizing PBM treatments are curative, not just temporary relief. It is time for the FDA to move forward.

After years of tragedy and death, the battle to rid America of opioid use disorder is starting to turn the tide. This promise of hope will become a reality only when PBM Therapy receives the funding, acceptance, and adoption it deserves.

SEEING THE LIGHT

Also published on Newsmax.  #PBMTherapyHeals

Imagine being successfully treated, painlessly and safely, for a wide range of diseases and conditions. Imagine having a cure for chronic pain.

This revolution in health and wellness is already available and will be celebrated on May 16 as the United Nations’ Annual International Day of Light.

On May 16, 1960, American physicist and engineer, Theodore Maiman, operated the first successful laser, achieving coherent and controllable light waves. This revolutionized manufacturing, communications, and health.

In 1967, Endre Mester in Semmelweis University Budapest, Hungary conducted studies to determine if lasers caused cancer. He shaved the hair from the bodies of mice, divided them into two groups and gave a laser treatment with a low powered ruby laser to one group. They did not get cancer. Instead the hair on the treated group grew back more quickly than the untreated group. The concept of "laser biostimulation" was discovered.

Today, “biostimulation” is known as Photobiomodulation (PBM). It is the process where a specific range of the light spectrum at the right intensity, when directed to the body for the right period of time, can restore the function of stressed cells to normal healthy operation. It is non-invasive, non-toxic, and has no reported side effects.

There are over 32 trillion cells in the human body. Each cell has hundreds of microscopic factories called mitochondria which combine oxygen with nutrients from the blood stream to make the cellular energy called ATP. This energy is used to help the cell live and to conduct its various roles in our body: keeping the heart beating, the brain thinking, the body moving, and the all the other functions that keep us alive and healthy.

Mester’s discovery was an epiphany. If specific light band waves can help cells to regrow hair, can they wake-up cells to do other things? Now over five-hundred human clinical trials and 4,000 laboratory studies have shown the answer to be an overwhelming YES!

PBM is now a common veterinary treatment for improving the lives of animals suffering from hip dysplasia and kidney failure. Throughout the world, forward thinking Doctors and Dentists are using PBM to successfully treat Oral Mucositis (side effect from chemotherapy), Dry Macular Degeneration, Multiple Sclerosis, Parkinson’s Disease, Lyme Disease, and diabetic wounds. It also reduces pain and inflammation in various orthopedic conditions such as tendonitis, neck pain, low back pain, and carpal tunnel syndrome.

Chronic pain costs Americans over $635 billion a year in additional healthcare costs and lost productivity. PBM is used for recovery and endurance by champion athletes. At the 2016 Rio Olympics, many Nike sponsored athletes used a whole body PBM product called NovoTHOR to help them train, recover, and win more medals. This led NFL, MLB, NHL and NBA teams to add “light beds” to their training regime.

A growing number of doctors and public health officials are exploring PBM therapy as an alternative pain treatment to Opioids. This may help solve the addiction crisis facing America.

If PBM is so effective, why is not everywhere?

Outside of the U.S. it is. Australia, Canada, England, the European Union, and NATO all recognize PBM, promote its use, and accept insurance coverage. The Food and Drug Administration (FDA) is slowly moving towards regulatory clearances for PBM light equipment to officially treat diseases and conditions. Currently, the FDA labels PBM devices in the basic category of infrared or heat lamps.

Until the FDA moves forward, U.S. insurance companies, except for a few BCBS affiliates, refuse to reimburse for PBM treatments. They remain a solid wall of resistance.

Medicare and Medicaid refuse to reimburse for PBM treatments. Federal Officials have labeled PBM “mumbo jumbo” and declared its successes “placebo effect”.

The International Day of Light is an opportunity to alert everyone who could benefit from PBM therapy of its existence and promise. It is a time to ask public officials about ways to bring PBM into the mainstream of American healthcare. It is a time to ask your Doctor, Dentist, Veterinarian, and local gym/wellness center if they offer PBM therapy and if not, why not.

May 16 is an annual reminder that bringing light therapy into healthcare is long overdue.

It is up to all of us, for ourselves, our families, and our communities, to make the promise of light a reality.

[Scot Faulkner advises global organizations and universities on healthcare reform and innovation. He served as the Chief Administrative Officer of the U.S. House of Representatives. He also served on the White House Staff, and as an Executive Branch Appointee.]